|
MechanismNF-kappa-B-repressing factor inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date23 Jul 2004 |
喜滴克(尿多酸肽注射液)联合化疗治疗晚期乳腺癌、非小细胞肺癌开放、多中心IV 期临床试验
[Translation] An open, multicenter Phase IV clinical trial of Xidic (uropolyacitide injection) combined with chemotherapy for the treatment of advanced breast cancer and non-small cell lung cancer
旨在评价国家I 类抗癌新药喜滴克上市后联合化疗用于治疗晚期乳腺癌、非 小细胞肺癌的安全性和临床获益。
[Translation] The aim is to evaluate the safety and clinical benefits of Xidic, a national Class I anticancer new drug, combined with chemotherapy for the treatment of advanced breast cancer and non-small cell lung cancer after its launch.
尿多酸肽注射液(CDA-Ⅱ)治疗低危、中危-1 骨髓增生异常综合征(MDS)随机开放、多中心II 期临床研究
[Translation] A randomized, open, multicenter phase II clinical study of CDA-Ⅱ in the treatment of low-risk and intermediate-risk myelodysplastic syndrome (MDS)
主要目的:评价CDA-Ⅱ治疗IPSS 评分为低危、中危-1 的MDS 患者的血液学改善(HI)率; 次要目的:输血需求变化、观察完全缓解(CR)和部分缓解(PR)、血液学改善(HI)维持时间、生活质量(QLQ)和安全性。
[Translation] Primary objective: To evaluate the hematological improvement (HI) rate of MDS patients with low-risk and intermediate-risk-1 IPSS scores treated with CDA-Ⅱ; Secondary objectives: Changes in transfusion requirements, observation of complete remission (CR) and partial remission (PR), duration of hematological improvement (HI), quality of life (QLQ) and safety.
100 Clinical Results associated with Hefei Everlife Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Hefei Everlife Pharmaceutical Co., Ltd.
100 Deals associated with Hefei Everlife Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Hefei Everlife Pharmaceutical Co., Ltd.